Drug intelligence / Profile preview

KUR-212

Development stage: Phase 2
Lead developer: Kuros Biosciences
Modality: Recombinant Proteins and Enzymes
Administration: Topical

Overview

KUR-212 (also known as I-020502) is a recombinant protein drug developed for use in wound healing, specifically to enhance the healing of autologous meshed skin grafts. Its mechanism of action involves stimulation of fibrinogen and agonism at platelet-derived growth factor receptors (PDGFRs), promoting tissue repair and regeneration. The drug has been evaluated in phase II clinical trials for its safety and efficacy in patients undergoing skin autografting procedures. It was originally developed by Kuros Biosciences.

Targets

PDGFR (PDGFR family)

Beyond the preview

Go deeper on KUR-212.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KUR-212.

Explore the full profile